Kris Chavez, Founder & Chief Operating Officer

Kris brings extensive leadership experience in all stages of
biopharmaceutical development involving antibodies, peptides and
small molecules.  Prior to founding Innomab, Kris was Vice-
President for Project Management at Cambridge Antibody
Technology (CAT) Inc. where she was responsible for Program
Management.  Kris was Project Director at Genencor developing
an HBV vaccine and immunotoxins in oncology.  At  Nektar
(Inhale), Kris  developed antibody treatments for asthma, chronic
obstructive pulmonary disease and multiple sclerosis.  She led the
Project Management function at Oread, Inc., a contract research
organization.  Prior to that she had a successful 20+ year career at
Syntex/Roche where she held a number of increasingly
responsible CMC positions. She earned her B.A. in Biological
Sciences from the University of California, Berkeley.

Kim Graham, Founder & Chief Executive Officer

Kim brings extensive leadership skills.  Prior to forming Innomab,
Kim was General Manager and Director of Cambridge Antibody
Technology,  Inc., responsible for the CAT US site and projects.
Over his career, Kim has contributed to the development of
numerous successfully-marketed pharmaceutical products.  Kim's
experience includes Vice-President of Drug Development and Vice-
President and Director of Drug Evaluation at Roche Bioscience
along with numerous development positions of increasing
responsibility at Syntex.  Over a 19-year period at Syntex, he rose
to Vice-President and Director of the multi-country New Molecules
Program Management Team. Kim currently sits on AbGenomics
International Inc.’s  Board of Directors. Kim has a B.A. from
Stanford University and an M.A. from the University of Oregon,
both in Biology.

Chuck Smith, MD, PhD, Founder & Chief Medical Officer

Chuck brings extensive clinical development industry experience
with emphasis in early stage oncology. Prior to Innomab, Chuck
was Vice-President, Clinical Development at Cambridge Antibody
Technology.  He also led Clinical Development at Genencor.  At
Novartis' Oncology headquarters, Chuck had a six-year stint where
he led the international clinical development of several novel
compounds.  Chuck trained in Internal Medicine at the Albert
Einstein College of Medicine, New York City and was a Clinical
Associate at the National Cancer Institute (NCI) in Bethesda,
Maryland. Chuck is licensed to practice medicine and has been
certified by the American Board of Internal Medicine.  Chuck holds
M.D. & Ph.D. degrees  from the State University of New York,
Downstate Medical Center, and a from The
Pennsylvania State University.
Management Team
Kris Chavez Chief Operating Officer of Innomab
Kim Graham Chief Executive Officer of Innomab
Innomab Logo
Chuck Smith, M.D., Ph.D. Chief Medical Officer of Innomab